Advanced Dosage Forms Inc., the Canadian partner to Imprimis Pharmaceuticals, will begin a clinical trial of the Dropless TriMoxi formulation for cataract surgery, according to a press release.
The prospective, randomized, controlled, multicenter, crossover study will enroll 200 bilateral cataract surgery patients to compare Dropless TriMoxi (triamcinolone acetonide-moxifloxacin) to traditional eye drop therapy to assess drug safety, patient preference and pharmacoeconomic measures, the release said.
“The goal of the study is to clinically validate the experience of American
Uncategorized